2191-219X
Yes
EJNMMI RES
0
91
GERMANY
http://ejnmmires.springeropen.com/
3.0影响因子
核医学小学科
59/212JIF RANK
2848总被引频次
月期刊平台服务过的文章录用时间为1-3个月,依据20年经验,经月期刊专家预审通过后的文章,投稿通过率100%以上!
EJNMMI研究在核医学和分子成像领域发表了新的基础、转化和临床研究。常规功能包括原创研究文章,快速交流创新研究的初步数据,有趣的案例报告,社论,以及给编辑的信件。也欢迎有关基础科学、基础方面的教育文章,以及与临床前研究和临床研究或伦理方面的研究有关的争议。及时的综述提供了核医学和分子成像技术的当前应用、成像研究中的问题和转化方面的最新进展。主要重点放在在分子探针的更广泛背景下发展放射性药物的靶向成像,以增进对潜在疾病的复杂生物学过程的了解和特征描述,并开发、测试和指导包括放射性核素治疗在内的新治疗模式。
https://www.editorialmanager.com/ejre/default.aspx
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.